The weather has been unfolding rather slowly; however, Mother Nature can’t remain sluggish for long. And once her warm, sunny ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study In this pilot study, we assessed the adoptive T-cell ...

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

A dealership's rating is based on all of their reviews, with more weight given to recent reviews. Want to share your experience with this dealership? Everyone was helpful and friendly. It was a ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

SAN FRAN­CIS­CO — Ben Aus­pitz, a vet­er­an biotech in­vestor and re­peat en­tre­pre­neur, is re­unit­ing with long­time col­lab­o­ra­tor Alex­is Borisy and his “free the ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...